Filing Flows › Amneal Pharmaceuticals (AMRX) › Net income
Amneal Pharmaceuticals (AMRX) net income by quarter
Amneal Pharmaceuticals' net income was $12.3M in Q3 2026 (third quarter 2026), -79% from Q2 2026. Over the last 6 quarters it ranged from $12.2M (Q1 2025) to $62.3M (Q1 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $12.3M | -79% | — |
| Q2 2026 | $57.7M | -7% | +157% |
| Q1 2026 | $62.3M | +77% | +411% |
| Q4 2025 | $35.1M | +56% | — |
| Q2 2025 | $22.4M | +84% | — |
| Q1 2025 | $12.2M | — | — |
Q3 2026 at a glance
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Amneal Pharmaceuticals' net income?
Amneal Pharmaceuticals' net income was $12.3M in Q3 2026 (third quarter 2026), -79% from Q2 2026.
How has Amneal Pharmaceuticals' net income changed?
Over the last 6 quarters it ranged from $12.2M (Q1 2025) to $62.3M (Q1 2026).
Q3 2026 results → · How Amneal Pharmaceuticals makes money →